Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
Mohamed Hosny Ismail Easa
34 participants
Sep 7, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.
Eligibility
Inclusion Criteria1
- Adults aged 35-65 years diagnosed with PHN. Persistent pain for at least 3 months after herpes zoster infection. Only patients who sign the informed consent form will be included.
Exclusion Criteria9
- Contraindications to taVNS such as:
- pregnancy;
- active implants (e.g., pacemakers, cochlear implants) or brain shunts;
- previous neurological or psychiatric diagnoses;
- history of addiction or substance abuse;
- history of trauma and/or brain surgery;
- cardiac disease;
- acute or chronic use of medications and/or illicit drugs;
- susceptibility to headaches and seizures. Severe cognitive impairment. Other chronic pain conditions.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07123987